
Blueprint Medicines Corporation BPMC
Quarterly report 2025-Q1
added 05-01-2025
Blueprint Medicines Corporation DSO Ratio 2011-2025 | BPMC
Annual DSO Ratio Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.5 | 48.6 | 43.5 | 32.7 | 1.78 | 128 | - | - | 47 | 109 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 128 | 1.78 | 56.7 |
Quarterly DSO Ratio Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | - | 53.7 | 47.9 | 48.8 | - | 61.3 | 51.6 | 38.6 | - | 13.4 | 35.9 | 39.2 | - | 82.8 | 101 | 88.3 | - | 0.87 | 77.6 | 57.4 | 1.17 | 6.62 | 11.8 | 45.4 | 5.65 | 5.33 | 0.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 | 0.07 | 40 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aptevo Therapeutics
APVO
|
79 | $ 0.58 | -3.71 % | $ 160 K | ||
|
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.03 | - | $ 234 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.15 | -0.63 % | $ 7.58 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 1.11 | -2.63 % | $ 6.05 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
132 | $ 211.38 | 1.15 % | $ 5 B | ||
|
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.17 | -18.42 % | $ 370 M | ||
|
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | ||
|
Catalyst Biosciences
CBIO
|
3.24 | $ 12.36 | 0.08 % | $ 814 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 26.84 | -1.03 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
77.3 | $ 9.52 | -0.37 % | $ 140 M | ||
|
Certara
CERT
|
88.6 | $ 8.86 | -0.39 % | $ 1.42 B | ||
|
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
94.5 | $ 4.9 | 3.16 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | ||
|
Axon Enterprise
AXON
|
134 | $ 580.39 | -0.59 % | $ 44 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
150 | $ 2.57 | 4.7 % | $ 16.1 M | ||
|
ChromaDex Corporation
CDXC
|
13.2 | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | ||
|
Celldex Therapeutics
CLDX
|
86.5 | $ 26.14 | -0.98 % | $ 1.68 M |